Department of Pharmaceutics, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing , China .
Drug Dev Ind Pharm. 2014 Jun;40(6):774-82. doi: 10.3109/03639045.2013.786723. Epub 2013 May 17.
Gambogic acid (GA) can inhibit the growth of various cancer cells. However, the low bioavailability caused by insolubility, limits its clinical application. L-arginine is always used with GA to form a complex to obtain the higher solubility. Moreover, guanidyl group from arginine, which can facilitate the cellular uptake, was identified.
In this study, L-arginine and chitosan (CS) were used for the first time to prepare N-octyl-N-arginine CS (OACS), a novel amphiphilic carrier for GA with solubility- and absorption-enhancing functions; the characterization of the GA loaded OACS micelles (GA-OACS) and its absorption-enhancing effect were also investigated.
GA-OACS were prepared by the dialysis method. The formed micelles were characterized and evaluated by atomic force microscope (AFM), dynamic light scattering, differential scanning calorimeter (DSC), solubility test, in vitro release and in situ intestinal perfusion.
The GA-OACS micelles were successfully prepared attaining a 35.3% drug loading and 82.2% entrapment efficiency. GA-OACS had a homogeneous particle size of 160.3 nm; +21.8 mv zeta potential with smooth continuous surface was observed by using AFM. DSC diagram suggested that GA was encapsulated in the micelles. Meanwhile, GA encapsulated in micelles exhibited a desirable slow release in vitro experiment. The solubility of GA in OACS micelles was increased up to 3.16 ± 0.13 mg/mL, 2320 times than that of free GA. The single pass perfusion showed that the absorption of GA-OACS micelles was enhanced 3.6-fold, 2.1-fold and 2.2-fold for jejunum, ileum and colon, respectively.
OACS provided excellent ability of drug loading, increasing solubility and enhanced absorption for GA, which indicated that OACS micelles as an oral drug delivery carrier may have potential research and application values.
藤黄酸(GA)可以抑制多种癌细胞的生长。然而,由于不溶性导致的低生物利用度限制了其临床应用。精氨酸通常与 GA 一起形成复合物以获得更高的溶解度。此外,已确定来自精氨酸的胍基基团可以促进细胞摄取。
本研究首次使用精氨酸和壳聚糖(CS)制备 N-辛基-N-精氨酸 CS(OACS),这是一种具有增溶和吸收增强功能的 GA 新型两亲载体;还研究了载 GA 的 OACS 胶束(GA-OACS)的表征及其吸收增强作用。
通过透析法制备 GA-OACS。通过原子力显微镜(AFM)、动态光散射、差示扫描量热法(DSC)、溶解度试验、体外释放和原位肠灌注对形成的胶束进行了表征和评价。
成功制备了 GA-OACS 胶束,载药量为 35.3%,包封率为 82.2%。GA-OACS 的粒径均一,为 160.3nm;通过 AFM 观察到+21.8mv 的 zeta 电位,表面光滑连续。DSC 图谱表明 GA 被包封在胶束中。同时,GA 包封在胶束中的体外释放实验显示出理想的缓慢释放。GA 在 OACS 胶束中的溶解度提高到 3.16±0.13mg/mL,是游离 GA 的 2320 倍。单次通过灌流实验表明,GA-OACS 胶束的吸收分别增强了 3.6 倍、2.1 倍和 2.2 倍,用于空肠、回肠和结肠。
OACS 为 GA 提供了出色的载药能力、增溶能力和增强吸收能力,表明 OACS 胶束作为口服药物递送载体具有潜在的研究和应用价值。